Based on epidemiologic data from patients with von Willebrand disease which showed approximately 40–60% fewer arterial thrombotic events in patients with VWF activity of about 25%28, we assumed that decreasing VWF activity to 20% or less is of therapeutic interest. This evidence concerns the gene VWF and platelet-type von Willebrand disease.